all report title image

Antibodies Market Analysis & Forecast: 2026-2033

Antibodies Market, By Drug Type (Monoclonal antibodies, Polyclonal antibodies, Antibody-drug complexes (ADCs), by Disease Indication (CNS Disorders, Cardiovascular, Cancer, Autoimmune Disorders, COVID-19, Others) By End User (Hospitals, Long-term Care Facilities, Research institutes), And by Region (North America, Latin America, Europe, Asia Pacific, Middle East, and Africa)

  • Published In : 28 Apr, 2026
  • Code : CMI2629
  • Page number :170
  • Formats :
      Excel and PDF :
  • Industry : Biotechnology
  • Historical Range : 2020 - 2024
  • Forecast Period : 2026-2033

Antibodies Market is estimated to be valued at USD 3,23,043.7 Mn in 2026 and is expected to reach USD 7,64,714.8 Mn in 2033, exhibiting a compound annual growth rate (CAGR) of 13.1% from 2026 to 2033.

Analysts’ Views on Global Antibodies Market: 

Increasing inorganic strategies such as collaborations by the key market players is expected to drive the global antibodies market over the forecast period. For instance, in March 2022, Sanofi, a pharmaceutical and healthcare company, and Seagen Inc., a biotechnology company, announced a collaboration agreement, to design, develop, and commercialize antibody-drug conjugates (ADCs) for up to three cancer targets. The collaboration will utilize Sanofi’s proprietary monoclonal antibody (mAb) technology and Seagen’s proprietary ADC technology

Figure 1. Global Antibodies Market Share (%), By Drug Type, 2026

ANTIBODIES MARKET

To learn more about this report, Download Free Sample

Global Antibodies Market – Driver

Increase in inorganic strategies

Increasing inorganic strategies such as collaboration by the key market players is expected to drive the global antibodies market over the forecast period. For instance, in September 2020, Eli Lilly and Company, a pharmaceutical company and Amgen, an U.S.

Figure 2. Global Antibodies Market Value (US$ Million), By Region, 2026

ANTIBODIES MARKET

To learn more about this report, Download Free Sample

Global Antibodies Market- Regional Analysis

Among regions, North America is estimated to hold a dominant position in the global antibodies market over the forecast period.   

The U.S. government has placed a pre-order for 100 million doses of Pfizer's BNT162b2 mRNA vaccine at a cost of $1.95 billion as early as July 22, 2020, and after one year, it has already placed orders for a total of 500 million doses.

Global Antibodies Market Segmentation:

The global antibodies market report is segmented into Drug Type, Disease Indication, End User, and Region

Based on Drug Type, the market is segmented into monoclonal antibodies, polyclonal antibodies, and antibody-drug complexes (ADCs). Out which the monoclonal antibodies segment is expected to hold a dominant position in the antibodies market over the forecast period.

Based Disease Indication, the antibodies market is segmented into CNS disorders, cardiovascular diseases, cancer, and autoimmune disorders.

Based on End User, the antibodies market is segmented into hospitals, long-term care facilities, and research institutes.

Antibodies Market Report Coverage

Report Coverage Details
Base Year: 2025 Market Size in 2026: USD 3,23,043.7 Mn
Historical Data for: 2020 To 2024 Forecast Period: 2026 To 2033
Forecast Period 2026 to 2033 CAGR: 13.1% 2033 Value Projection: USD 7,64,714.8 Mn
Geographies covered:
  • North America: U.S. and Canada
  • Latin America: Brazil, Argentina, Mexico, and Rest of Latin America
  • Europe: Germany, U.K., Spain, France, Italy, Russia, and Rest of Europe
  • Asia Pacific: China, India, Japan, Australia, South Korea, ASEAN, and Rest of Asia Pacific
  • Middle East: GCC Countries, Israel, and Rest of Middle East
  • Africa: South Africa, North Africa, and Central Africa
Segments covered:
  • By Drug Type: Monoclonal antibodies, Polyclonal antibodies, Antibody-drug complexes (ADCs)
  • By Disease Indication: CNS Disorders, Cardiovascular Diseases, Cancer, Autoimmune Disorders         
  • By End User: Hospitals, Long-term Care Facilities, Research institutes
Companies covered:

Novartis AG, F. Hoffmann-La Roche Ltd., Johnson & Johnson Services, Inc., Takeda Pharmaceutical Company Limited, Amgen Inc., Biogen Inc., Bristol-Myers Squibb Company, AbbVie Inc., Sanofi, Eli Lilly and Co., Iovance Biotherapeutics, Inc., Ultragenyx Pharmaceutical Inc., and Kyowa Kirin Co., Ltd.

Growth Drivers:
  • Increasing number of product approval by the regulatory authorities
Restraints & Challenges:
  • High cost of the antibody therapy
  • Side effects associated with the antibody administration 

Uncover macros and micros vetted on 75+ parameters: Get instant access to report

Global Antibodies Market Cross Sectional Analysis:

In drug type, the monoclonal antibodies segment is expected to hold a dominant position in the global antibodies market in North America over the forecast period. For instance, in October 2020, the U.S.

Global Antibodies Market: Key Developments

For instance, in October 2020, IAVI, a nonprofit scientific research organization, and Serum Institute of India Pvt.

Global Antibodies Market: Key Trends

Increasing authorizations for antibodies by the regulatory authorities

Increasing authorizations by the regulatory authorities is expected to drive the global antibodies market over the forecast period. For instance, in May 2021, Roche India, announced that the Central Drugs Standards Control Organization (CDSCO) has provided an Emergency Use Authorization (EUA) for Roche’s antibody cocktail (Casirivimab and Imdevimab) in India.

Global Antibodies Market: Restraint

Side effects associated with the antibodies

Use of antibodies may lead to some side effects such as serum sickness, acute anaphylaxis, and specific target-related adverse effects, which is also expected to hinder the market growth. To overcome the adverse effects of the drugs and antibodies, regulatory authorities should strictly monitor the products.

Global Antibodies Market - Key Players

Novartis AG, F. Hoffmann-La Roche Ltd., Johnson & Johnson Services, Inc., Takeda Pharmaceutical Company Limited, Amgen Inc., Biogen Inc., Bristol-Myers Squibb Company, AbbVie Inc., Sanofi, Lilly., Iovance Biotherapeutics, Inc., Ultragenyx Pharmaceutical Inc. and Kyowa Kirin Co., Ltd.

Sources

Primary Research Interviews

  • Therapeutic antibody developers (Roche, AbbVie, Merck, AstraZeneca, Regeneron)
  • CDMOs for monoclonal antibody manufacturing (Lonza, Samsung Biologics, WuXi Biologics)
  • Research antibody suppliers (Abcam, Cell Signaling, Thermo Fisher)

Databases

  • U.S. FDA Drug Approvals
  • ClinicalTrials.gov

Magazines

  • BioProcess International
  • GEN

Journals

  • mAbs (Taylor & Francis)
  • Nature Reviews Drug Discovery

Newspapers

  • Reuters Health

Associations

  • The Antibody Society
  • BIO

Public Domain Sources

  • U.S. FDA
  • European Medicines Agency (EMA)

Proprietary Elements

  • CMI Data Analytics Tool, Proprietary CMI Existing Repository of information for last 10 years.

*Definition: An antibody, also called immunoglobulin, is a protein produced by plasma cells in response to specific antigens. These antibodies can be used as therapeutic as well as diagnostic purposes for several indications, including cancers, autoimmune disorders, inflammatory & infectious diseases, and others.

Share

Share

About Author

Abhijeet Kale is a results-driven management consultant with five years of specialized experience in the biotech and clinical diagnostics sectors. With a strong background in scientific research and business strategy, Abhijeet helps organizations identify potential revenue pockets, and in turn helping clients with market entry strategies. He assists clients in developing robust strategies for navigating FDA and EMA requirements.

Missing comfort of reading report in your local language? Find your preferred language :

Frequently Asked Questions

The Antibodies Market is estimated to be valued at USD 3,23,043.7 Mn in 2026, and is expected to reach USD 7,64,714.8 Mn by 2033.

The CAGR of the Antibodies Market is projected to be 13.1% from 2026 to 2033.

Increasing in the product approval by the regulatory authorities is expected to drive the market.

Monoclonal antibodies segment is the leading drug type segment in the market.

High cost of the antibody therapy is expected to hinder the growth of the market.

Novartis AG, F. Hoffmann-La Roche Ltd., Johnson & Johnson Services, Inc., Takeda Pharmaceutical Company Limited, Amgen Inc., Biogen Inc., Bristol-Myers Squibb Company, AbbVie Inc., Sanofi, Eli Lilly and Co., Iovance Biotherapeutics, Inc., Ultragenyx Pharmaceutical Inc., and Kyowa Kirin Co., Ltd.
Logo

Credibility and Certifications

DUNS Registered

860519526

ESOMAR
Credibility and Certification

9001:2015

Credibility and Certification

27001:2022

Clutch
Credibility and Certification

Need a Custom Report?

We can customize every report - free of charge - including purchasing stand-alone sections or country-level reports

Customize Now

Select a License Type

EXISTING CLIENTELE

Joining thousands of companies around the world committed to making the Excellent Business Solutions.

View All Our Clients
trusted clients logo
© 2026 Coherent Market Insights Pvt Ltd. All Rights Reserved.